MiniMed Group (MMED) Q1 2027 earnings summary

Executive summary

• Achieved 16% organic revenue growth in Q1 FY27, surpassing expectations, with strong U.S. and international performance driven by new product launches and expanded sensor supply.

• U.S. revenue grew 13%, with new pumps sold up over 20% year-over-year, mainly from the MiniMed Flex launch targeting new and competitive conversions.

• International markets delivered double-digit growth, notably in Western Europe, supported by increased sensor availability and new product launches.

• Advanced multiple pipeline programs, including early CE mark for Flex, FDA submission for Fit, and completed pivotal trial enrollment for Vivera.

• Pipeline execution is ahead of schedule, with several regulatory milestones and product launches occurring earlier than planned.

Financial highlights

• Q1 FY27 revenue reached $843 million, up 16.6% as reported and 15.8% organic year-over-year, including a 4-6% benefit from an extra week.

• Adjusted EBITDA was $83 million, with a margin of 9.9%, impacted by accelerated investments and FX remeasurement charges.

• Adjusted gross margin was 55.9%, ahead of expectations, with improved yields on Simplera sensors.

• Consumables and CGM represented 82% of revenue, providing a stable recurring revenue base.

• Free cash flow was $21 million, excluding separation and standup costs; cash balance at quarter-end was $207 million, with no debt and a $500 million undrawn revolver.

Outlook and guidance

• Fiscal 2027 organic revenue growth guidance raised to approximately 10.5%, including a 1.0–1.5% benefit from the extra week.

• Adjusted EBITDA margin guidance reaffirmed at approximately 16% for fiscal 2027, expecting margin expansion in the second half.

• Anticipate continued growth in new pumps sold and CGM attachment rates as new products roll out globally.